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Summary
A model is developed for chronic diseases with an indolent phase that is followed by a phase with 
more active disease resulting in progression and damage. The time scales for the intensity func-
tions for the active phase are more naturally based on the time since the start of the active phase, 
corresponding to a semi-Markov formulation. This two-phase model enables one to fit a separate 
regression model for the duration of the indolent phase and intensity-based models for the more 
active second phase. In cohort studies for which the disease status is only known at a series of 
clinical assessment times, transition times are interval-censored, which means the time origin for 
phase II is interval-censored. Weakly parametric models with piecewise constant baseline haz-
ard and rate functions are specified, and an expectation-maximization algorithm is described for 
model fitting. Simulation studies examining the performance of the proposed model show good 
performance under maximum likelihood and two-stage estimation. An application to data from 
the motivating study of disease progression in psoriatic arthritis illustrates the procedure and iden-
tifies new human leukocyte antigens associated with the duration of the indolent phase.
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1 INTRODUCTION
1.1 DISEASE PROCESSES WITH DELAYED ACTIVITY
Many chronic disease processes feature considerable variability in their course which must be dealt
with in statistical analysis for valid inference. Regression modeling and regression diagnostics play a
2central role in explaining this variation in such a way that scientific understanding can be advanced.
Another avenue is to generalize the family of stochastic models considered as the basis for analysis.
Finite mixture models, for example, offer an appealing generalization as they involve conceptualiza-
tion of two or more subpopulations of individuals, each with different stochastic models generating
the response process. When models are directed at dynamic aspects of disease processes the sim-
plest and perhaps most studied mixture model accommodates a non-susceptible sub-population of
individuals whose status will never change, while individuals in the complementary sub-population
experience the disease process. Such models are often called cure-rate models when modeling the
time to an event (Farewell, 1986) or mover-stayer models when considering multistate disease pro-
cesses (Goodman, 1961, Frydman, 1984).
In many contexts it is unnatural to envision diseased individuals as being indefinitely at zero risk
of disease activity or damage. An alternative, and less extreme assumption is to consider two phases
of the disease course: an indolent phase (phase I) during which affected individuals do not experi-
ence clinically meaningful disease activity or damage and an active phase II of disease progression.
Chronic diseases whose course can be represented in this way include HIV/AIDS where phase I rep-
resents the period of HIV infection prior to the manifestation of AIDS defining events, and phase
II represents the onset of opportunistic infections or death. In diabetes there may be a long phase I
period during which no symptoms are evident, followed by a second phase during which there is evi-
dence of retinopathy, nephropathy or other types of vascular impairment. Individuals with hepatitis C
infection may go a long time without experiencing any liver cirrhosis but will ultimately experience
progressive liver damage. Finally arthritis patients may simply have elevated markers of inflammation
for some time before there is any evidence of joint damage, but once joint damage begins the risk of
continued damage is substantially greater.
Phase I may be viewed as ending upon the occurrence of a precipitating event which signals the
beginning of a fundamentally different period (phase II) in which activity and damage are realized.
The nature of the morbidity process will drive the specification of the stochastic model for this phase.
Often the dynamics of the disease process are sufficiently distinct in this phase that it is natural to
define the time origin as the time of the transition from phase I to phase II. With this in mind we
formulate a partially semi-Markov two-phase model in which one part characterizes the duration of
phase I and another part characterizes the dynamic disease process during the second phase. The term
partially semi-Markov is used because the time origin is redefined only once, at the start of the second
phase. This model can be used to separately examine prognostic factors for the length of the indolent
phase as well as factors prognostic for the nature and rate of change in the active phase. In some
settings this will offer a more appropriate representation of complex multi-phase disease processes,
can help identify different types of risk factors, and could yield more accurate prediction models.
The remainder of the paper is organized as follows. In the next sub-section we describe the data
from the University of Toronto Psoriatic Arthritis Cohort which motivates this work. In Section 2 we
define notation and describe the two-part model using a general multistate process to characterize the
second phase where the time origin for the second phase is the time of the precipitative event. We also
discuss likelihood construction when individuals are examined intermittently rendering the time of the
precipitating event and subsequent transition times as interval-censored. In Section 3 we consider a
special case of the general phase II model of Section 2 which is specified to correspond to the data
from the motivating study. Specifically, the response of interest is intermittent counts of the number
of damaged joints experienced by patients with a rheumatological disease, so we consider an analysis
based on proportional rate models. We then develop an expectation-maximization algorithm (Demp-
ster et al., 1977) for estimation under a model with piecewise constant intensities. A computationally
more convenient two-stage estimation procedure is discussed in Section 4 in which the parameters in
the hazard for the end of phase I are estimated using standard likelihood for interval-censored data.
The results of simulation studies examining the finite sample performance of estimators obtained by
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maximum likelihood and the two-stage procedure are given in Section 5, along with an application
to the motivating study. Concluding remarks and topics for further research are provided in Section
6. Derivations of the formula for large sample variance estimations under maximum likelihood and
two-stage estimation are given in appendices.
1.2 THE UNIVERSITY OF TORONTO PSORIATIC ARTHRITIS COHORT
The Centre for Prognosis Studies in Rheumatic Disease is a tertiary care center at the Toronto Western
Hospital which treats patients with a variety of rheumatological conditions and maintains several
clinic registries with prospective follow-up. One registry is of patients with psoriatic arthritis (PsA),
an immunological disease which features both skin (psoriasis) and joint (arthritis) involvement. The
psoriatic aspect of the condition arises from an overproduction of new skin cells resulting in red and
white scaly patches of skin frequently located on the elbows, knees and scalp. As with other arthritic
conditions, this disease can result in considerable inflammation and ultimately destruction of joints,
which can lead to serious disability and poor quality of life (Chandran et al., 2010). This registry was
established in 1976 and has been recruiting and following patients since its inception, and today it is
one of the largest cohorts of patients with PsA in the world.
Patients in this registry undergo a detailed clinical and radiological examination upon entry to the
clinic, and provide serum samples for genetic testing. Follow-up clinical and radiological assessments
are scheduled annually and biannually respectively in order to track changes in joint damage. At
each radiological assessment the degree of damage is recorded in sixty-four joints on a five-point
scale (Rahman et al., 1998). To date 1191 patients have been recruited to the University of Toronto
Psoriatic Arthritis Clinic. Of these 604 have undergone genetic testing to determine their human
leukocyte antigen profile. Among these individuals the median time from clinic entry to the last
radiological assessment is 6.3 years with a median of 3 radiological assessments per patient.
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Figure 1: Plot of assessment times (hatch marks) and time of radiological damaged joints detected
between assessments (solid points) from onset of psoriatic arthritis for a selected sample of patients
from the University of Toronto Psoriatic Arthritis Clinic. The dashed line denotes time from disease
onset to first occurrence of joint damage, and the solid line denotes the period of disease progression
following onset of damage.
We focus our modeling here on the accumulation of joint damage reflected by the total number
of joints with at least grade 4 damage according to the Steinbrocker scoring system (Wu and Cook,
42015). Figure 1 shows the time course of damage for a sample of five individuals. The horizontal axis
reflects the time from disease onset and the length of the individual lines reflects the extent of follow-
up of each individual; visits at which joint counts are made are represented by vertical tick marks.
The dashed portion of each individuals timeline reflects the period during which no joint damage
occurred, and the solid parts of the timelines reflect periods over which joint damage occurred. Of
course the precise times at which joints became damaged are not available so for graphical illustration
times were uniformly generated over the intervals during which they were known to occur; the dots
are located at the resulting times.
From these illustrative timelines is apparent that some individuals develop joint damage shortly
after diagnosis (e.g. individuals 1 and 3) while some enjoy a long period of time without damage
(e.g. individuals 2, 4 and 5). Moreover, it appears that once the first joint becomes damaged, for some
individuals other joints rapidly become damaged while for other individuals the rate of subsequent
damage is low. Separate modeling of these two aspects of the disease process (the duration of the
indolent phase, and the rate of damage in the active phase) are the focus of the two-part model we
describe in the next section.
2 MODEL FORMULATION AND LIKELIHOOD UNDER INTERMITTENT OBSER-
VATION
2.1 GENERAL FORMULATION OF A TWO-PHASE MODEL
We consider chronic diseases that feature a variable and potentially long phase I during which there
are no clinically important manifestations of disease in affected individuals. If t denotes the time since
disease onset, we let T1 be a random variable representing the duration of phase I with t1 representing
its realization. The second phase of the process takes place over t > t1 when the disease is in an active
period manifest by, for example, the occurrence of exacerbations or flares of symptoms, disability, or
in the motivating rheumatological context, joint damage and destruction. The variable duration of
the indolent period (phase I) and the distinct nature of disease activity in the active period (phase II)
motivates the time scale for phase II defined based on t∗ = t− t1, which is simply the time since the
end of phase I.
For a general presentation we consider a multistate disease process {Z(t∗), 0 < t∗} for phase II
which has a countable state space with states labeled by positive integers {1, 2, . . . , }. Transitions
may occur between any states in this general formulation with transitions governed, given T1 = t1,
by Markov intensities in terms of time t∗. In Section 3.1 we consider the special case of a progressive
multistate model for which only k − 1→ k transitions can occur.
To unify the notation for the two phases we augment the state space for the process in phase II to
include a state 0 representing the status prior to T1, and write Z¯(t) = Z(t∗)I(t1 ≤ t) and consider
models for the stochastic process
{
Z¯(t), 0 < t
}
; note that Z(t∗) = Z¯(t1 + t∗). We let X be a p × 1
vector of fixed covariates. The two-phase model can be defined by first considering the hazard for the
end of phase I, defined by
lim
∆t↓0
P (t ≤ T1 < t+ ∆t|t ≤ T1, X)
∆t
= h(t|X) . (2.1)
Covariate effects can be modeled using proportional (Cox, 1972), additive (Aalen, 1989), or hybrid
Cox-Aalen models (Martinussen and Scheike, 2007). We let H(t∗) = {Z(u), 0 < u < t∗, x} be the
history of the process in phase II, and dynamic aspects of the process can be modeled through intensity
functions (Andersen et al., 2012) given by
lim
∆t↓0
P (Z (t∗ + ∆t−) = k|Z(t∗−) = j,H(t∗))
∆t
= Yj(t
∗)λjk(t∗|H(t∗)) , (2.2)
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where Yj(t∗) = I(Z(t∗−) = j), j ∈ {1, 2, . . .}. If H¯(t) =
{
Z¯(u), 0 < u < t, x
}
denotes the history
since the time of disease onset, then the intensity
lim
∆t↓0
P
(
Z¯(t+ ∆t−) = k|Z¯(t−) = j, H¯(t))
∆t
= Y¯j(t)λ¯jk(t|H¯(t)) , (2.3)
governs the full process from disease onset, where Y¯j(t) = I(Z¯(t−) = j) indicates whether an
individual is at risk of a transition out of state j ∈ {0, 1, . . .} at time t. Note that if we denote (2.1)
as λ01(t|H¯(t)}, then we can write λ¯jk(t|H¯(t)) = λjk(B(t)|H¯(t)) where B(t) = I(t ≤ t1)t + I(t1 <
t)(t − t1). Thus the process {Z¯(t), 0 < t} has a countable number of states in the state space and a
semi-Markov feature in that the relevant time scale for the second phase of the disease process is the
time since the end of phase I. With this time scale the process in phase II is Markov, but we refer to
the process as a whole as partially semi-Markov process.
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Figure 2: Lexis diagram of event and assessment times on the scale of disease duration (t) on the
horizontal axis and the time since start of phase II (t∗) on the vertical axis.
The probability of a particular path P of this multistate process given X = x is
∞∏
j=0
∏
k∈Zj
 ∏
tr∈D¯jk
λ¯jk(tr|H¯(tr))
 exp
(
−
∫ ∞
0
Y¯j(u)λ¯jk(u|H¯(u))du
) , (2.4)
where Zj is the set of states that can be entered directly from state j and D¯jk is the set of j → k
transition times (Andersen and Keiding, 2002). This can be written more explicitly as
λ01(t1|x) exp
(
−
∫ ∞
0
Y¯0(u)λ01(u|x)du
)
(2.5)
×
 ∞∏
j=1
∏
k∈Zk
 ∏
t∗r∈Djk
λjk(t
∗
r|H(t∗r))
 exp
(
−
∫ ∞
0
Yj(u)λjk(u|H(u))du
) ,
where if tr ∈ D¯jk, each t∗r ∈ Djk can be expressible as t∗r = tr − t1. A slightly modified version
of this probability expression can be derived for likelihood contributions when processes are under
conditionally independent and non-informative censoring. Instead of pursuing this we consider next
the problem of estimation and inference when such processes are under intermittent observation so
that all event times are interval-censored.
62.2 INTERMITTENT ASSESSMENT AND INTERVAL-CENSORED DATA
Here we consider the setting in which individuals are intermittently assessed and discuss the likeli-
hood construction; for simplicity in what follows, we consider the contribution from a single indi-
vidual. Let a0 = 0 denote the onset time of disease and a1 < · · · < aR denote the times of the R
assessments at which point the individual’s condition, and hence response status, is determined. The
observed history at a−r is denoted by H(ar) =
{
(a`, Z¯(a`)), ` = 0, 1, . . . , r − 1, X
}
, where we use a
standard font for H(·) to distinguish it from the history of the process in continuous time. With fixed
covariates, the full likelihood is
L ∝ P (Z¯(a0), A0 = a0, X)× R∏
r=1
P
(
Z¯(ar), Ar = ar|H(ar)
)
. (2.6)
We can omit the first term in the full likelihood if we condition on the covariate and the state
occupied (0) at the onset of disease. We also assume the “sequential missing at random” condition
(Hogan et al., 2004) holds so that if an individual is observed up to ar−1, then conditional on the event
history at that time, the probability they are lost to follow-up and not observed at ar cannot depend
on events in [ar−1, ar). We also assume the event process and inspection process are conditionally
independent and that the inspection process is non-informative. Under these assumptions, we can
focus on the partial likelihood of the form
L ∝
R∏
r=1
P
(
Z¯(ar)|H(ar)
)
. (2.7)
This observed data partial likelihood (2.7) can be maximized directly, but this can be challenging
if the dimension of parameters is high and the expression of this likelihood is complicated due to
intermittent assessment. Therefore, an expectation-maximization (EM) algorithm (Dempster et al.,
1977) can alternatively be used with a complete data likelihood analogous to observed data likelihood
where missing variables, in this case the transition time from phase I to phase II, are part of the com-
plete data. This is a particularly attractive approach for the setting of piecewise constant intensities
which we consider in the next section.
3 AN EXPECTATION-MAXIMIZATION ALGORITHM
3.1 THE COMPLETE DATA LOG-LIKELIHOOD
The complete data likelihood (2.5) is given in general form for the case in which we consider the
event times as observed, or subject at most to right-censoring. In this section, we redefine the notation
by giving a superscript 1 or 2 to denote the part. Here we consider the setting with interval-censored
data in phase I and let a10 = 0 denote the onset of disease and a
1
1 < · · · < a1R1 denote the times of R1
assessments at which point the individual’s disease stage is determined. For information in phase II
it is helpful to let a20 = 0 denote the start time of phase II and a
2
1 < · · · < a2R2 denote the times of the
R2 radiological assessments during phase II. With the process in phase II a recurrent event process
we can also let nr = Z¯(a2r)− Z¯(a2r−1) denote the number of events over the interval Ar = (a2r−1, a2r],
r = 1, . . . , R2.
We adopt a Poisson process model for phase II such that λk,k+1(t∗|H(t∗)) = ρ(t∗|x) and write the
complete data likelihood (2.5) as
L ∝ λ01(t1|X) exp
(
−
∫ ∞
0
Y¯0(u)λ01(u|X)du
)
×
R2∏
r=1
[
1
nr!
{∫ a2r
a2r−1
ρ(u|X)du
}nr
exp
{
−
∫ a2r
a2r−1
ρ(u|X)du
}]
.
(3.1)
Ying Wu and Richard J. Cook 7
We consider multiplicative models of the form λ01(t1|X; θ1) = h0(t1;α1) exp(X ′β1) for T1|X and
λk,k+1(t
∗|H(t∗)) = ρ0(t∗;α2) exp(X ′β2) for the recurrent event process in phase II, where k ≥ 1,
where α1 indexes the baseline hazard function, α2 indexes the baseline rate function, θ1 = (α′1, β
′
1)
′,
θ2 = (α
′
2, β
′
2)
′ and θ = (θ′1, θ
′
2)
′. A weakly parametric piecewise exponential baseline hazard is
adopted for the duration of phase I and a piecewise constant baseline rate model is adopted for the
recurrent event process during phase II. These require specification of break-points where the baseline
hazard and rate functions can take on different values and we denote these by 0 = b10 < b
1
1 < · · · < b1K1
and 0 = b20 < b
2
1 < · · · < b2K2 respectively. Then we let
h0(t;α1) = α1k if t ∈ B1k = [b1k−1, b1k) k = 1, . . . , K1,
ρ0(t
∗;α2) = α2k if t∗ ∈ B2k = [b2k−1, b2k) k = 1, . . . , K2 ,
(3.2)
respectively. We consider all the subintervals Crk = Ar ∩ B2k of length urk and let nrk denote the
unobserved number of events over Crk such that
∑K2
k=1 nrk = nr, r = 1, . . . , R2. Since Nrk|T1, X ∼
Poisson(µrk) , where µrk = α2kurk exp(X ′β2), then
E (Nrk|T1, X,Nr) = nr · α2kurk/
∑K2
k=1 α2kurk .
The complete data log-likelihood is then
logLC(θ) = logLC1(θ1) + logLC2(θ2) , (3.3)
where
logLC1(θ1) = δ1
{
K1∑
k=1
Ik(t1) (logα1k +X
′β1)−
K1∑
k=1
α1kWk(t1)e
X′β1
}
− (1− δ1)
K1∑
k=1
α1kWk(aR1)e
X′β1 ,
(3.4)
logLC2(θ2) = δ1
{
R2∑
r=1
K2∑
k=1
nrk (logα2k +X
′β2)−
R2∑
r=1
K2∑
k=1
α2kurke
X′β2
}
, (3.5)
Ik(u) = I(u ∈ B1k) and Wk(u) =
∫ u
0
Ik(s)ds is the total time at risk in B1k over the interval (0, u],
k = 1, . . . , K1 and δ1 = I(T1 < aR1) is the status indicator whether the precipitating event is
observed.
3.2 THE EM ALGORITHM FOR MAXIMUM LIKELIHOOD ESTIMATION
At the vth iteration of the expectation-maximization (EM) algorithm, the E-Step is to take the condi-
tional expectation
Q(θ; θ(v)) = Q1(θ1; θ
(v)) +Q2(θ2; θ
(v)) , (3.6)
where Q1(θ1; θ(v)) = E
[
logLC1(θ1)|D; θ(v)
]
and Q2(θ2; θ(v)) = E
[
logLC2(θ2)|D; θ(v)
]
, where the
observed data is D =
{
(ar, Z¯(ar)), r = 0, 1, . . . , R1, X
}
. The unobserved quantities in the complete
data log likelihood Ik(t1), Wk(t1), nrk and urk are all functions of T1. Thus, their conditional expec-
tations given the current estimates of parameters and the observed data D can be evaluated through
ft1|D(t1|D; θ) =
f1(t1)×
R2∏
r=1
f2(nr|t1)∫ R1
L1
f1(u1)×
R2∏
r=1
f2(nr|u1) du1
, (3.7)
8where
f(t1|X) =
K1∏
k=1
{
[α1k exp(X
′β1)]
Ik(t1) · exp (−α1kWk(t1) exp(X ′β1))
}
and
f2(nr|t1, X) =
[
K2∑
k=1
α2kurk exp(X
′β2)
]nr
· exp
(
−
K2∑
k=1
α2kurk exp(X
′β2)
)
.
The M-Step involves maximizing Q(θ; θ(v)) with respect to θ and get the updated estimate θ(v+1). By
reparametrization, we can write Q(θ; θ(v)) in the form of a Poisson log-likelihood and use existing
software for generalized linear model to maximize following the creation of a pseudo-dataset. We
iterate between the E-step and M-step until the convergence criterion
∣∣(θ(v+1) − θ(v)) /θ(v)∣∣ <  is
achieved where  is the user-specified tolerance. The details of the EM algorithm and the calculation
of conditional expectations are given in Appendix A.
4 TWO-STAGE ESTIMATION
Instead of simultaneously estimating all the parameters in the full likelihood function (3.3), a two-
stage estimation procedure can be adopted. Under this approach in the first stage we note that we can
simply view T1 as an interval-censored failure time with a hazard function indexed by θ1. For this the
pertinent data can be denoted by C1 = [L1, R1), the interval known to contain T1 and X . Here we let
QI(·) denote the corresponding function in (3.6) under a two-stage procedure where
QI(θ1; θ
(v)
1 ) = δ1
[
K1∑
k=1
ιˆ
(v)
k
(
logα1k +X
′β1
)− K1∑
k=1
ω̂
(v)
k α1ke
X′β1
]
− (1− δ1)
K1∑
k=1
α1kWk(aR1)e
X′β1 ,
(4.1)
ιˆ
(v)
k = E{Ik(t1)|C1, x; θ(v)1 } and ω̂(v)k = E{Wk(t1)|C1, x; θ(v)1 }. The conditional distribution of T1
given C1 andX takes on a simpler form in this framework with f(t1|C1, X; θ(v)1 ) = f1(t1)/
∫ R1
L1
f1(u1)du1
given by
f(t1|C1, X; θ(v)1 ) =
[
K1∏
k=1
α
Ik(t1)
1k ]× exp(−
∑K1
k=1 α1kWk(t1) exp(X
′β1))∫ R1
L1
[
∏K1
k=1 α
Ik(u1)
1k ]× exp(−
∑K1
k=1 α1kWk(u1) exp(X
′β1))du1
. (4.2)
The expectations are therefore easier to carry out, and the maximization step is as before. Specifically
(4.1) can be written as a Poisson log-likelihood and existing software can be used to maximize it
following the creation of a pseudo-dataset as in Section 3.
In the second stage, θ2 can be estimated via a modified expectation-maximization algorithm de-
fined by plugging in the estimates of θ̂1 from stage one into the function QII(θ2; θ̂1, θ
(v)
2 ) defined as
QII(θ2; θ̂1, θ
(v)
2 ) =
R2∑
r=1
K2∑
k=1
δ1
{
n̂
(v)
rk (logα2k +X
′β2)− α2kû(v)rk exp(X ′β2)
}
, (4.3)
where ûrk = E[urk|D; θ̂1, θ(v)2 ] and n̂(v)rk = E[nrα(v)2k urk/
∑K2
k=1 α
(v)
2k urk|D; θ̂1, θ(v)2 ]. The conditional
expectations in the second stage are based on (3.7) evaluated at θ̂1 and θ
(v)
2 given the full set of
observed data D. The objective function (4.3) can be rewritten to take the form of a Poisson log-
likelihood and maximized using existing software as before. This two-stage estimation approach is
quite similar to the method of simultaneous estimation we described in Section 3.2; however, this
approach is computationally faster, particularly when the number of parameters is large. Variance es-
timation of the resulting estimation is discussed in Appendix C. We comment further on the potential
uses of this two-stage procedure in the Discussion.
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5 SIMULATION STUDIES AND APPLICATION
5.1 DESIGN AND INTERPRETATION OF SIMULATION STUDIES
In this section, a simulation study is conducted to demonstrate the performance of proposed two-phase
model. For each individual i, a p × 1 covariate vector Xi is generated from a multivariate normal
distribution with mean 0 and a covariance matrix Σ, where p = 2, Σij = %|i−j| and % = 0.5. The
duration of the indolent phase T1 is generated from an exponential distribution with rate α1 exp(X ′iβ1).
We set β1 = (0.5, 0.5)′ and solve for the value of the baseline rate α1 such that F (C) =
∫
x
P (T1 <
C|x)P (x)dx = 0.8, where C = 50 is the administrative censoring time. The gap times between
the consecutive events are generated by an exponential distribution with rate α2 exp(X ′iβ2), where
β2 = (−0.5,−0.5) and α2 = 0.5.
We let Ri denote the number of assessments for individual i, which is generated according to a
truncated Poisson distribution to ensure at least one follow-up assessment, with
P (Ri = ri|Ri ≥ 1;µ) = µ
ri exp(−µ)
ri! {1− exp(−µ)} , ri = 1, . . . .
where µ = 10. The Ri inspection times 0 < ai1 < · · · < aiRi < C are then uniformly distributed
over [0, C]. The number of events occurring between assessments are then mir =
∑ni
j=1 I(ai,r−1 <
tij ≤ ai,r), r = 1, . . . , Ri. We consider a sample size of m = 500 and simulate five hundred datasets
(nsim = 500). For each dataset, we fit the proposed two-phase model by the EM algorithm under
both simultaneous (maximum likelihood) and two-stage estimation; the empirical performance of
estimators are shown in Table 1. The break-points were chosen for the phase I model as the quartiles
of the baseline survival distribution. For the second phase, they are chosen to be equally spaced over
[0, C − Q501 ] (i.e. we used (C − Q501 )/4, (C − Q501 )/2 and 3(C − Q501 )/4) where Q501 is the median
of T1; in Table 1 for example (C − Q501 )/4 = 9.23. Standard errors for the maximum likelihood
estimators were obtained by Louis (Louis, 1982) (see Appendix B) and using estimating function
theory (see Appendix C). The empirical coverage probabilities were computed as the proportion of
all simulated datasets for which the 95% confidence interval contained the true parameter value.
The empirical performance of the estimators using both estimation approaches are shown in Ta-
ble 1, where the empirical biases (EBIAS) are generally small. There is good agreement between the
empirical standard errors (ESE) and average standard errors (ASE) obtained by Louis (Louis, 1982)
or the methods of Appendix C respectively and the empirical coverage probabilities (ECP) are all
compatible with the nominal level. From the simulation results, we can conclude that both estimation
approaches give good performance; the empirical biases are relatively small and the empirical cov-
erage probabilities are all compatible with the nominal 95% level. Moreover, there is relatively little
efficiency loss from the two-stage estimation procedure.
5.2 APPLICATION OF PSORIATIC ARTHRITIS DATA
Here we consider the data on joint damage in patients with psoriatic arthritis from the University of
Toronto Psoriatic Arthritis Clinic. Specific interest lies in examining the effects of human leukocyte
antigen (HLA) markers on the duration of the indolent phase following diagnosis and on the rate of
joint damage following the end of the indolent phase. The breakpoints for the model of the duration of
the indolent phase are 3.5, 9.2, 13.7 and 26 years, specified to correspond to points yielding roughly
equal increments in the nonparametric Turnbull estimate of the the cumulative probability function
for the time to the precipitating event (the time the first joint becomes damaged). The breakpoints
for the second phase were taken as 8.2, 12.6, 17.0 and 23.5 years, likewise corresponding to roughly
equal increments in the estimate of the mean function for the cumulative number of damaged joints
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Table 1: Empirical performance† of estimators; sample sizem = 500, number of simulations nsim =
500, α1 = 0.036, α2 = 0.5, β1 = (0.5, 0.5), β2 = (−0.5,−0.5); ASE are average of standard
errors estimated via methods in Appendix B (Maximum Likelihood) and Appendix C (Two-Stage
Estimation).
MAXIMUM LIKELIHOOD TWO-STAGE ESTIMATION
PIECE PARAMETER EBIAS ESE ASE ECP EBIAS ESE ASE ECP
PHASE I: ONSET OF DAMAGE
[0.00, 5.38) α11 -0.014 0.447 0.431 94.6 -0.005 0.475 0.457 93.8
[5.38, 13.05) α12 0.008 0.445 0.452 95.6 0.004 0.484 0.496 95.4
[13.05, 25.26) α13 0.021 0.413 0.427 95.6 0.008 0.447 0.458 96.4
[25.26, 50.00) α14 0.042 0.450 0.440 94.4 0.052 0.456 0.451 94.4
β11 0.968 6.491 6.494 95.4 1.000 6.449 6.538 95.6
β12 0.654 6.431 6.447 96.6 0.621 6.467 6.488 97.2
PHASE II: PROGRESSION OF DAMAGE
[0.00, 9.23) α21 -0.163 1.626 1.622 95.2 -0.167 1.626 1.623 95.0
[9.23, 18.46) α22 0.031 1.763 1.815 95.6 0.030 1.760 1.815 95.6
[18.46, 27.68) α23 0.104 2.071 1.994 94.8 0.103 2.068 1.994 94.8
[27.68, 50.00) α24 -0.003 1.781 1.702 93.2 -0.003 1.780 1.702 93.2
β21 -0.117 1.669 1.691 95.4 -0.118 1.669 1.691 95.2
β22 0.039 1.617 1.686 96.4 0.037 1.617 1.686 96.4
† EBIAS, ESE and ASE reported are ×102
N(t) obtained based on isotonic regression. We examine the effects of HLA markers selected based
on the results of Wu and Cook (Wu and Cook, 2015), while controlling for gender and patient age.
As in the empirical studies, we find from the results in Table 2 that there is good agreement in the
estimates obtained by the simultaneous and two-stage estimation procedures. We therefore discuss
the results of maximum likelihood estimation here. Among the HLA markers, HLA-A11, HLA-A25,
HLA-A29, HLA-A30, HLA-C03 and HA-DRB1-10 had insignificant association with the duration of
the indolent phase but their presence was associated with a significant reduction of the rate of damage
in the active phase of the disease. For HLA-A11 for example, the relative rate of damage in the active
phase associated with the presence of HLA-A11 is RR = 0.70 (95% CI : 0.53, 0.91; p = 0.0087);
the corresponding relative rates for the other markers were HLA-A25 RR = 0.07 (95% CI : 0.01,
0.53; p = 0.0096), HLA-A29 RR = 0.25 (95% CI : 0.15, 0.43; p < 0.0001), HLA-A30 RR = 0.78
(95% CI : 0.63, 0.97; p = 0.0235), HLA-C03 RR = 0.57 (95% CI : 0.47, 0.70; p < 0.0001),
and HLA-DRB1-10 RR = 0.04 (95% CI : 0.01, 0.27; p = 0.0011). Moreover, there is significant
evidence that the effect of HLA-A25, HLA-A30, HLA-C03, and HLA-DRB1-10 on the duration of
the indolent phase and on damage progression are different; see the last column of Table 2 for the
homogeneity p−values. HLA-B27 is a known risk factor for disease progression in PsA and here we
find its presence is associated with both a shorter indolent phase and more rapid disease progression;
the same can be said for HLA-DQB1-02.
Figure 3 displays estimates of the probability of having at least one damaged joint as measured
by the time from disease onset (left panel) as well as the expected number of damaged joints from the
time of disease onset (right panel). The dashed lines in the left panel represents a nonparametric Turn-
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Table 2: Results of fitting a piecewise constant baseline hazard model for the duration of the indo-
lent period and a piecewise constant baseline rate model for the occurrence of joint damage under
simultaneous (ML) and two-stage estimation; p−values are based on Wald tests.
MAXIMUM LIKELIHOOD TWO-STAGE ESTIMATION
HLA Marker PHASE EST SE p p† EST SE p p†
HLA-A11 I -0.280 0.274 0.3079 -0.315 0.274 0.2506
II -0.363 0.138 0.0087 0.7876 -0.358 0.139 0.0098 0.8905
HLA-A25 I -0.211 0.597 0.7242 -0.159 0.597 0.7900
II -2.627 1.014 0.0096 0.0407 -2.614 1.015 0.0100 0.0378
HLA-A29 I -0.597 0.371 0.1076 -0.601 0.371 0.1055
II -1.377 0.270 < 0.0001 0.0899 -1.375 0.270 < 0.0001 0.0925
HLA-A30 I 0.458 0.295 0.1208 0.364 0.299 0.2243
II -0.250 0.110 0.0235 0.0256 -0.249 0.110 0.0244 0.0564
HLA-B27 I 0.468 0.183 0.0105 0.490 0.183 0.0074
II 0.235 0.067 0.0004 0.2333 0.237 0.067 0.0004 0.1957
HLA-C03 I 0.014 0.219 0.9480 0.017 0.220 0.9367
II -0.563 0.103 < 0.0001 0.0178 -0.566 0.103 < 0.0001 0.0169
HLA-C04 I -0.012 0.224 0.9576 0.011 0.225 0.9606
II -0.120 0.106 0.2565 0.6650 -0.122 0.107 0.2568 0.5985
HLA-DQB1-02 I 0.386 0.164 0.0187 0.394 0.164 0.0163
II 0.249 0.062 < 0.0001 0.4365 0.252 0.063 < 0.0001 0.4215
HLA-DRB1-10 I 0.203 0.594 0.7326 0.195 0.594 0.7428
II -3.280 1.002 0.0011 0.0028 -3.275 1.002 0.0011 0.0029
p†: a p-value from a test of homogeneity.
bull estimate (Turnbull, 1976) of the distribution of the duration of phase I based on interval-censored
T1 times. The solid line denotes the piecewise constant estimate from our proposed two-phase model
under simultaneous estimation of the phase I and II parameters. The dotted line gives an estimate
obtained by fitting a Poisson process to the interval-grouped joint damage data (Lawless and Zhan,
1998) and computing the probability of no damaged joints. The close alignment of the nonparametric
and proposed estimator suggests the piecewise constant hazards model gives a reasonable representa-
tion of the data and the large disparity between the Poisson-based estimate highlights the importance
of accommodating the two phases of the disease process. The steep rise in the probability of at least
one joint becoming damaged under the Poisson model is in conflict with the data.
The right panel of Figure 3 gives estimates of the expected number of damaged joints over time. A
nonparametric isotonic estimate (Barlow et al., 1972) is displayed with a dashed line and a solid line
gives the estimate under the proposed model with a piecewise constant baseline rate. Again Poisson
model is used to fit the data as a benchmark and displayed with a dotted line. It can be seen that
the benchmark analysis will overestimate the expected number of damaged joints and the proposed
two-phase model is comparable with the nonparametric analyses. This demonstrates the proposed
two-phase model fits the data well and supports the need to address the heterogeneity in the disease
process in this way.
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Figure 3: Estimates of the probability of having at least one damaged joint as measured from the time
since disease onset (left panel) and the expected number of damaged joints as function of the time
since disease onset (right panel); a benchmark analysis is based on a Poisson process with interval-
grouped recurrent event data (Lawless and Zhan, 1998); the nonparametric estimate for the duration
of phase I is based on a Turnbull estimate (Turnbull, 1976) and an isotonic estimate (Barlow et al.,
1972) for the expected number of damaged joints respectively.
6 DISCUSSION
There are several avenues for generalizations of this work including the use of semiparametric models
for the time from disease onset to the event signalling the beginning of the second phase of the
process. Much work has been done in the last twenty years on the development of flexible regression
methodology and statistical theory for the analysis of interval-censored failure time data (Sun, 2006).
A more challenging generalization would be to relax the Markov assumption for the second phase
process; this is challenging since not many alternative models can be easily fitted when processes
are under intermittent observation. In the general multistate formulation of Section 2 much work
has been done on methods for fitting and assessing Markov models in this setting but semi-Markov
and models with hybrid time scales have seen little development. Mixed effect models which are
Markov conditional on latent random effects however, have been developed and render more elaborate
dependencies on the process history. The conditional Markov property enables one to fit these models
even when the historical information is unobserved. For the recurrent event model we consider in
Section 3 this would correspond to a mixed Poisson model for the second phase of the process which
would be negative binomial if a gamma distributed random effect were introduced. Large data sets
would be required to estimate parameters in this more flexible model.
Another generalization of interest would be to integrate survival data into the disease process.
This would introduce an absorbing state which would of course terminate the disease process. The
primary purpose of this method is to separate the two phases of the morbidity process and to obtain
separate estimates of the effects of genetic markers; the effects of these markers are thought to be fairly
robust to violations of the assumption of independent mortality but this represents an area worthy of
development. Scientists at the University of Toronto Psoriatic Arthritis Cohort are undertaking tracing
studies to collect data on survival status of individuals who have not been to the clinic for some time.
With this additional information more comprehensive models could be considered which incorporate
survival data.
We have carried out tests of the null hypothesis of common coefficients for the phase I and II
regression models. If the null hypothesis is not rejected for a particular marker, one could consider
fitting a model with the constraint that the effects are the same. The algorithm can be adapted to handle
this but given the quite different interpretation of the effects in the two phases we have not considered
that here. It would also be of interest to assess whether there is evidence of a need for the two-phase
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model because estimation, inferences and model interpretation would be so much easier if the second
phase model were adequate. Such a test would be analogous to tests for the need to accommodate
a non-susceptible fraction in cure rate models, but in this context this is more challenging since the
time scale for the second phase model is defined as the time from the precipitating event.
Identification of important genetic and soluble biomarkers is of primary interest in psoriatic arthri-
tis and the two-phase model offers an important opportunity to identify factors that may be prognostic
for different aspects of the disease process. Given that a particular marker may be entertained in
both parts of the model one could consider the use of the group LASSO (Yuan and Lin, 2005, Wang
and Leng, 2008) by defining pairs of coefficients for each marker, with one coefficient defined in the
regression model for the phase I duration and another defined in the phase II model. Variations of
this such as the sparse group LASSO (Simon et al., 2013) could be useful in GWAS analyses but the
standard group LASSO would be sufficient for the analysis of haplotype data.
Often cohort data are created from registries which required individuals to have experienced some
disease manifestation for enrolment. This can lead to a biased sampling scheme arising due to trunca-
tion of the disease process. Researchers may require individuals to not have experienced disease ac-
tivity or damage to be eligible for an inception cohort, which would result in right-truncated interval-
censored duration times for the first phase. Cohorts of individuals with advanced disease may require
progression to some advanced state of the second phase process yielding right-truncated phase I and
II data. The expectation-maximization algorithm we describe can be adapted to accommodate left-,
right- and interval-truncation by the conceptualization of “ghosts” in the spirit of Turnbull (Turnbull,
1976). Such a complete data likelihood will be possible to fit with penalty terms using standard
software for penalized Poisson regression.
APPENDIX
A EVALUATION OF Q(θ; θ(v)) FOR MAXIMUM LIKELIHOOD ESTIMATION
A.1 DETAILS OF EM ALGORITHM
Here we show the details of the EM algorithm we described in Section 3.2. At vth iteration, we
proceed as follows:
1. Evaluate ι˜(v)k = E[Ik(t1)|D; θ(v)] and ω˜(v)k = E[Wk(t1)|D; θ(v)]. Then
Q1(θ1; θ
(v)) = δ1
{
K1∑
k=1
ι˜
(v)
k (logα1k + x
′β1)−
K1∑
k=1
α1kω˜
(v)
k e
x′β1
}
−(1− δ1)
(
K1∑
k=1
α1kWk(aR1)e
x′β1
)
.
(A.1)
2. Maximize Q1(θ1; θ(v)) to get the updated estimate of θ1, θ
(v+1)
1 .
LetZk = (Zk1, . . . , ZkK1)
′ denote the indicator function, whereZk` = I(k = `), ` = 1, . . . , K1.
Let αk = logα1k, k = 1, . . . , K1 and α = (α1, . . . , αK1)
′, then we can write
Q1(θ; θ
(v)) =
K1∑
k=1
[
δ1
{
ι˜
(v)
k (z
′
kα + x
′β1)− ω˜(v)k ez
′
kα+x
′β1
}
− (1− δ1)Wk(aR1)ez
′
kα+x
′β1
]
.
(A.2)
We note that (A.2) has a Poisson form of log likelihood function, then we can use existing
software (glm) to maximize it by creating a pseudo-dataset in the following format, as shown
in Table A.1.
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Table A.1: Pseudo-dataframe for the maximization of Q1
ID (i) piece (k) Zk1 Zk2 · · · ZkK1 X1 · · · Xp Response Offset
δ1 = 1
i 1 1 0 · · · 0 x1 · · · xp ι˜(v)1 log ω˜(v)1
i 2 0 1 · · · 0 x1 · · · xp ι˜(v)2 log ω˜(v)2
...
...
...
...
...
...
...
...
...
i K1 0 0 · · · 1 x1 · · · xp ι˜(v)K1 log ω˜
(v)
K1
δ1 = 0
i 1 1 0 · · · 0 x1 · · · xp 0 logW1(aR1)
i 2 0 1 · · · 0 x1 · · · xp 0 logW2(aR1)
...
...
...
...
...
...
...
...
...
i K1 0 0 · · · 1 x1 · · · xp 0 logWK1(aR1)
3. Evaluate u˜(v)rk = E[urk|D; θ(v+1)1 , θ(v)2 ] and n˜(v)rk = nrE[α(v)2k urk/
∑K2
k=1 α
(v)
2k urk|D; θ(v+1)1 , θ(v)2 ].
Then
Q2(θ2; θ
(v+1)
1 , θ
(v)
2 )
=ET1ENrk|T1
[
logLC2(θ2)|D; θ(v+1)1 , θ(v)2
]
=δ1E
[
R2∑
r=1
K2∑
k=1
{
nr
α
(v)
2k urk∑K2
k=1 α
(v)
2k urk
(logα2k + x
′β2)− α2kurk exp(x′β2)
}
|D; θ(v+1)1 , θ(v)2
]
=
R2∑
r=1
K2∑
k=1
δ1
{
n˜
(v)
rk (logα2k + x
′β2)− α2ku˜(v)rk exp(x′β2)
}
.
(A.3)
4. MaximizeQ2(θ; θ
(v+1)
1 , θ
(v)
2 ) to get the updated estimate of θ2, θ
(v+1)
2 . LetZk = (Zk1, . . . , ZkK2)
′
denote the indicator function, where Zk` = I(k = `), ` = 1, . . . , K2. Let γk = logα2k,
k = 1, . . . , K and γ = (γ1, . . . , γK1)
′, then we can write
Q2(θ; θ
(v+1)
1 , θ
(v)
2 ) =
R2∑
r=1
K2∑
k=1
δ1
{
n˜
(v)
rk (z
′
kγ + x
′β2)− u˜(v)rk exp(z′kγ + x′β2)
}
. (A.4)
We note that (A.4) has a Poisson form of log likelihood function, then we can use existing
software (glm) to maximize it by creating a pseudo dataset in the following format, as shown
in Table A.2.
A.2 EVALUATIONS OF THE CONDITIONAL EXPECTATIONS IN THE E-STEP
Since all the unobserved quantities are related to T1, we need conditional expectations in the form of∫ R1
L1
f(x)dx .
Due to the complicated nature of the function f(x), closed form expressions are not available so we
use numerical integration. Here we describe the Gaussian Quadrature which we used in the analyses.
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Table A.2: Pseudo-dataframe for the maximization of Q2
ID (i) assess (r) piece (k) Zk1 Zk2 · · · ZkK2 X1 · · · Xp Response Offset
i 1 1 1 0 · · · 0 x1 · · · xp n˜(v)11 log u˜(v)11
i 1 2 0 1 · · · 0 x1 · · · xp n˜(v)12 log u˜(v)12
...
...
...
...
...
...
...
...
...
i 1 K2 0 0 · · · 1 x1 · · · xp n˜(v)1K2 log u˜
(v)
1K2
...
...
...
...
...
...
...
i R2 1 1 0 · · · 0 x1 · · · xp n˜(v)R2,1 log u˜
(v)
R2,1
i R2 2 0 1 · · · 0 x1 · · · xp n˜(v)R2,2 log u˜
(v)
R2,2
...
...
...
...
...
...
...
...
...
i R2 K2 0 0 · · · 1 x1 · · · xp n˜(v)R2,K2 log u˜
(v)
R2,K2
First we can use a linear transformation to change this integration into a new integration on the
interval (−1, 1).
Let x = φ(y) = {y(R1− L1) + L1 +R1} /2, so∫ R1
L1
f(x)dx =
∫ 1
−1
f(φ(y))φ′(y)dy .
Then using Chebyshev quadrature (Golub and Welsch, 1969) of the 1st kind with the weight function
w(y) = 1/
√
1− y2 , we approximate the integration by:∫ R1
L1
f(x)dx =
∫ 1
−1
f(φ(y))φ′(y)dy =
∫ 1
−1
w(y)
f(φ(y))φ′(y)
w(y)
dy
.
=
∫ 1
−1
w(y)g(y)dy =
N∑
s=1
wsg(ys) ,
where ws and ys are the weights and nodes that are picked based on weight function w(y). Monte
Carlo methods with rejection sampling could alternatively be used to approximate these expectations
by simulation.
B LOUIS’ METHOD FOR ESTIMATES OBTAINED BY SIMULTANEOUS MAXI-
MIZATION
Here we describe how to implement Louis’ (Louis, 1982) method based on the identity
IOBS(θ) =
m∑
i=1
E[ICi(θ)|Di]−
m∑
i=1
E[Si(θ)S
′
i(θ)|Di] +
m∑
i=1
E[Si(θ)|Di]{E[Si(θ)|Di]}′ . (B.1)
For simplicity, hereafter we drop the subscript i and only consider a single observation. Then the
complete data score function, obtained from (3.3), is
S(θ) = (S ′1(θ1), S
′
2(θ2))
′
, (B.2)
16
where S1(θ1) = (S ′11(θ1), S
′
12(θ1))
′ with S11(θ1) = ∂ logLC(θ)/∂α1 and S12(θ1) = ∂ logLC(θ)/∂β1,
and S2(θ2) = (S ′21(θ2), S
′
22(θ2))
′ with S21(θ2) = ∂ logLC(θ)/∂α2 and S22(θ2) = ∂ logLC(θ)/∂β2.
The corresponding contribution to the complete data information matrix is then
Ii = −

∂2 logLC(θ)
∂α1∂α
′
1
∂2 logLC(θ)
∂α1∂β
′
1
0 0
∂2 logLC(θ)
∂β1∂α
′
1
∂2 logLC(θ)
∂β1∂β
′
1
0 0
0 0
∂2 logLC(θ)
∂α2∂α
′
2
∂2 logLC(θ)
∂α2∂β
′
2
0 0
∂2 logLC(θ)
∂β2∂α
′
2
∂2 logLC(θ)
∂β2∂β
′
2

.
For the specific models we consider,
∂ logLC(θ)
∂α1k
= δ1
{
Ik(t1)
α1k
− α1kWk(t1)ex′β1
}
− (1− δ1)α1kWk(aR1)ex
′β1 , k = 1, 2, . . . , K1 ,
∂ logLC(θ)
∂β1
= δ1
{
K1∑
k=1
(
Ik(t1)− α1kWk(t1)ex′β1
)}
x− (1− δ1)
{
K1∑
k=1
α1kWk(aR1)e
x′β1
}
x ,
∂ logLC(θ)
∂α2k
= δ1
R2∑
r=1
(
nrk
α2k
− urkex′β2
)
= δ1
R2∑
r=1
(
nrurk∑K2
j=1 α2jurj
− urkex′β2
)
, k = 1, 2, . . . , K2 ,
∂ logLC(θ)
∂β2
= δ1
R2∑
r=1
K2∑
k=1
(
nrk − α2kurkex′β2
)
x = δ1
(
n−
R2∑
r=1
K2∑
k=1
α2kurke
x′β2
)
x ,
− ∂
2 logLC(θ)
∂α1j∂α1k
= 0 , j 6= k ,
− ∂
2 logLC(θ)
∂α21k
= δ1
Ik(t1)
α21k
, k = 1, 2, . . . , K1 ,
− ∂
2 logLC(θ)
∂β1∂α1k
= δ1Wk(t1)e
x′β1x+ (1− δ1)Wk(aR1)ex
′β1x ,
− ∂
2 logLC(θ)
∂β1∂β
′
1
= δ1
{
K1∑
k=1
α1kWk(t1)e
x′β1
}
xx
′
+ (1− δ1)
{
K1∑
k=1
α1kWk(aR1)e
x′β1
}
xx
′
,
− ∂
2 logLC(θ)
∂α2k∂α2`
= δ1
R2∑
r=1
nrurkur`(∑K2
j=1 α2jurj
)2 , k, ` = 1, 2, . . . , K2 ,
− ∂
2 logLC(θ)
∂β2∂α2k
= δ1
R2∑
r=1
K2∑
k=1
urke
x′β2x ,
− ∂
2 logLC(θ)
∂β2∂β
′
2
= δ1
R2∑
r=1
K2∑
k=1
α2kurke
x′β2xx
′
.
The conditional expectations can be evaluated by Gaussian Quadrature described above and based
on the conditional probability density function (3.7). And to obtain the variance estimate, we need
the inverse of the observed information matrix, thus in this case, we need to solve a high dimensional
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matrix. Instead of using the solve function, we used ginv function in MASS library (or chol2inv
function).
C VARIANCE ESTIMATION FOLLOWING TWO-STAGE ESTIMATION
We estimate the asymptotic covariance matrix in the spirit of parametric two-stage estimation proce-
dure; see Newey and McFadden (Newey and McFadden, 1994). The complete data score functions
are shown in (B.2). For the simultaneous estimation approach, we solve the following estimating
functions:
U(θ) = 0 ,
where
U(θ) =

U11(θ1, θ2)
U12(θ1, θ2)
U21(θ1, θ2)
U22(θ1, θ2)
 =

E [S11(θ1)|D; θ1, θ2]
E [S12(θ1)|D; θ1, θ2]
E [S21(θ2)|D; θ1, θ2]
E [S22(θ2)|D; θ1, θ2]
 . (C.1)
For the two-stage estimation approach, in the first stage we solve
U∗1 (θ1) =
(
U∗11(θ1)
U∗12(θ1)
)
=
(
E [S11(θ1)|C1, X; θ1]
E [S12(θ1)|C1, X; θ1]
)
= 0 , (C.2)
and in the second stage we solve
U∗2 (θ2) =
(
U∗21(θ2)
U∗22(θ2)
)
=
(
E[S21(θ2)|D; θ̂1, θ2]
E[S22(θ2)|D; θ̂1, θ2]
)
= 0 . (C.3)
Thus at the second stage of the two-stage procedure we plug θ̂1 into (C.1) and estimate θ2 by solving
the resulting equation. LetU1(θ1, θ2) = (U ′11(θ1, θ2), U
′
12(θ1, θ2))
′, U2(θ1, θ2) = (U ′21(θ1, θ2), U
′
22(θ1, θ2))
′,
and U∗2 (θ2) = U2(θ̂1, θ2). Then if θ0 = (θ
′
10, θ
′
20)
′ denotes the true value of θ, consider the Taylor ex-
pansion of the score function U∗2 (θ2) around θ0 and evaluate it at θ̂2 giving,
0 = U∗2 (θ̂2) = U2(θ̂1, θ̂2) = U2(θ10, θ20)+
∂U2(θ10, θ20)
∂θ1
(
θ̂1 − θ10
)
+
∂U2(θ10, θ20)
∂θ2
(
θ̂2 − θ20
)
+op(n
1/2) .
Also
0 = U∗1 (θ̂1) = U
∗
1 (θ10) +
∂U∗1 (θ10)
∂θ1
(
θ̂1 − θ10
)
+ op(n
1/2) ,
therefore,
(
U∗1 (θ10)
U2(θ10, θ20)
)
= −
 ∂U
∗
1 (θ10)
∂θ1
0
∂U2(θ10, θ20)
∂θ1
∂U2(θ10, θ20)
∂θ2
( θ̂1 − θ10
θ̂2 − θ20
)
.
As n→∞, by the law of large numbers
− 1
n
 ∂U
∗
1 (θ10)
∂θ1
0
∂U2(θ10, θ20)
∂θ1
∂U2(θ10, θ20)
∂θ2
 p−→ ( I∗11 0
I21 I22
)
, A ,
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and by the central limit theorem,
1√
n
(
U∗1 (θ10)
U2(θ10, θ20)
)
d−→ N(0, B) , where B =
(
I∗11 0
0 I22
)
.
Therefore,
√
n
(
θ̂1 − θ10
θ̂2 − θ20
)
d−→ N(0, A−1BA−1′) .
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